Azuma I - Search Results

1

Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine.

Yoo YC, Yoshimatsu K, Koike Y, Hatsuse R, Yamanishi K, Tanishita O, Arikawa J, Azuma I. Yoo YC, et al. Among authors: azuma i. Vaccine. 1998 Jan-Feb;16(2-3):216-24. doi: 10.1016/s0264-410x(97)00188-6. Vaccine. 1998. PMID: 9607033

2

B30-MDP, a synthetic muramyl dipeptide derivative for tumour vaccination to enhance antitumour immunity and antimetastatic effect in mice.

Yoo YC, Saiki I, Sato K, Azuma I. Yoo YC, et al. Among authors: azuma i. Vaccine. 1992;10(11):792-7. doi: 10.1016/0264-410x(92)90515-l. Vaccine. 1992. PMID: 1441733

3

Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen.

Tamura M, Yoo YC, Yoshimatsu K, Yoshida R, Oka T, Ohkuma K, Arikawa J, Azuma I. Tamura M, et al. Among authors: azuma i. Vaccine. 1995 Jan;13(1):77-82. doi: 10.1016/0264-410x(95)80015-6. Vaccine. 1995. PMID: 7762283

4

MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.

Yoo YC, Saiki I, Sato K, Azuma I. Yoo YC, et al. Among authors: azuma i. Vaccine. 1994 Feb;12(2):175-60. doi: 10.1016/0264-410x(94)90057-4. Vaccine. 1994. PMID: 8147100

5

Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins.

Yoshimatsu K, Yoo YC, Yoshida R, Ishihara C, Azuma I, Arikawa J. Yoshimatsu K, et al. Among authors: azuma i. Arch Virol. 1993;130(3-4):365-76. doi: 10.1007/BF01309667. Arch Virol. 1993. PMID: 8517793

6

Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice.

Yoo YC, Yoshimatsu K, Hatsuse R, Tamura M, Yoshida R, Tono-oka S, Arikawa J, Azuma I. Yoo YC, et al. Among authors: azuma i. Vaccine. 1995 Oct;13(14):1300-5. doi: 10.1016/0264-410x(95)00041-x. Vaccine. 1995. PMID: 8585284

7

Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus.

Fukushima A, Yoo YC, Yoshimatsu K, Matsuzawa K, Tamura M, Tono-oka S, Taniguchi K, Urasawa S, Arikawa J, Azuma I. Fukushima A, et al. Among authors: azuma i. Vaccine. 1996 Apr;14(6):485-91. doi: 10.1016/0264-410x(95)00236-t. Vaccine. 1996. PMID: 8782344

8

Protective effect of mucosal administration of recombinant human macrophage colony-stimulating factor (rhM-CSF) on mucosal infection of Sendai virus in mice.

Matsuzawa K, Yoo YC, Fukushima A, Yoshimatsu K, Arikawa J, Azuma I. Matsuzawa K, et al. Among authors: azuma i. Vaccine. 1997 Jan;15(1):85-9. doi: 10.1016/s0264-410x(96)00106-5. Vaccine. 1997. PMID: 9041671

9

Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.

Koike Y, Yoo YC, Mitobe M, Oka T, Okuma K, Tono-oka S, Azuma I. Koike Y, et al. Among authors: azuma i. Vaccine. 1998 Dec;16(20):1982-9. doi: 10.1016/s0264-410x(98)00084-x. Vaccine. 1998. PMID: 9796054

10

Inhibitory effect of trehalose dimycolate (TDM) and its stereoisometric derivatives, trehalose dicorynomycolates (TDCMs), with low toxicity on lung metastasis of tumour cells in mice.

Watanabe R, Yoo YC, Hata K, Mitobe M, Koike Y, Nishizawa M, Garcia DM, Nobuchi Y, Imagawa H, Yamada H, Azuma I. Watanabe R, et al. Among authors: azuma i. Vaccine. 1999 Mar 17;17(11-12):1484-92. doi: 10.1016/s0264-410x(98)00367-3. Vaccine. 1999. PMID: 10195785

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

495 results

Search Page

Filters